文献速递心脑血管急症重症综合管理与镇静镇痛

吸入氙气对院外心脏骤停昏迷幸存者心功能的影响

Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest-A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial.
PubMed 文献 · Crit Care Explor · 2021-07-29
一句话结论在院外心脏骤停昏迷幸存者中,吸入氙气联合低温治疗与更好的左室收缩功能恢复相关,但该亚组研究样本小、需进一步验证。

该研究为氙气联合低温治疗心脏骤停试验的探索性亚组研究,纳入38例(17例氙气组、21例对照组)有完整超声心动图的院外心脏骤停昏迷幸存者,随机接受吸入氙气联合33°C低温24小时或单纯低温治疗。结果显示,低温后氙气组左室射血分数高于对照组(50%±10% vs 42%±10%,p=0.014),整体纵向收缩应变也优于对照组(-14.4%±4.0% vs -10.5%±4.0%,p=0.006),而舒张功能无组间差异。提示氙气可能促进左室收缩功能恢复,但样本量小,结论需谨慎解读。

要点

  • 在院外心脏骤停昏迷幸存者中,氙气联合33°C低温24小时组低温后左室射血分数高于单纯低温组(50%±10% vs 42%±10%,p=0.014)。
  • 氙气组低温后整体纵向收缩应变优于对照组(-14.4%±4.0% vs -10.5%±4.0%,p=0.006),提示收缩功能恢复更好。
  • 两组舒张功能指标无显著变化,氙气对舒张功能无明显影响。
  • 在合并冠心病的患者中,氙气组非缺血心肌节段的纵向应变改善。
  • 该研究为探索性亚组分析,仅38例有完整超声心动图,样本量小,结果需进一步验证。

适用人群与场景

  • 院外心脏骤停后昏迷幸存者,初始心律为可电击心律,年龄24-76岁,来自两个大学医院的多功能ICU。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 随机接受吸入氙气联合低温治疗(33°C)24小时,或单纯低温治疗;氙气具体剂量、给药途径和频次原文未提及。
  • 超声心动图在入院时和低温后24±4小时进行,评估左室射血分数、心肌纵向收缩应变和舒张功能。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:随机、两组、单盲、2期临床药物试验的探索性亚组研究;样本量:38例有完整超声心动图(氙气组17例,对照组21例);中心数:两个大学医院。
  • 主要终点:低温后左室射血分数氙气组高于对照组(50%±10% vs 42%±10%,p=0.014);入院时两组相似(39%±10% vs 38%±11%,p=0.711)。
  • 关键次要终点:整体纵向收缩应变低温后氙气组优于对照组(-14.4%±4.0% vs -10.5%±4.0%,p=0.006);入院时相似(-9.0%±3.8% vs -8.1%±3.6%,p=0.555)。
  • 舒张功能:两组间无变化。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:随机对照试验的探索性亚组研究(单盲、2期);证据等级或推荐强度:原文未提及。
  • 局限:样本量小(仅38例有完整超声心动图),为亚组分析,单盲设计,两个中心,结果需进一步验证;原文未提及其他局限。

对床旁实践的改变

  • 该研究提示在院外心脏骤停昏迷幸存者中,吸入氙气联合低温治疗可能促进左室收缩功能恢复,但样本量小,不能作为常规推荐;适用人群为初始可电击心律的院外心脏骤停昏迷幸存者,不适用于其他人群。
  • 常见陷阱:不能将研究方案中的氙气剂量或用法外推至临床实践,原文未提供具体剂量信息;需注意该研究为探索性亚组分析,结果需谨慎解读。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: This explorative substudy aimed at determining the effect of inhaled xenon on left ventricular function by echocardiography in comatose survivors of out-of-hospital cardiac arrest.

DESIGN: A randomized two-group single-blinded phase 2 clinical drug trial.

SETTING: A multipurpose ICU in two university hospitals.

PATIENTS: Of the 110 randomized comatose survivors after out-of-hospital cardiac arrest with a shockable rhythm in the xenon in combination with hypothermia after cardiac arrest trial, 38 patients (24-76 yr old) with complete echocardiography were included in this study.

INTERVENTIONS: Patients were randomized to receive either inhaled xenon combined with hypothermia (33°C) for 24 hours or hypothermia treatment alone. Echocardiography was performed at hospital admission and 24 ± 4 hours after hypothermia.

MEASUREMENTS AND MAIN RESULTS: Left ventricular ejection fraction, myocardial longitudinal systolic strain, and diastolic function were analyzed blinded to treatment. There were 17 xenon and 21 control patients in whom echocardiography was completed. Clinical characteristics did not differ significantly between the groups. At admission, ejection fraction was similar in xenon and control patients (39% ± 10% vs 38% ± 11%; p = 0.711) but higher in xenon than control patients after hypothermia (50% ± 10% vs 42% ± 10%; p = 0.014). Global longitudinal systolic strain was similar in xenon and control patients at admission (-9.0% ± 3.8% vs -8.1% ± 3.6%; p = 0.555) but better in xenon than control patients after hypothermia (-14.4.0% ± 4.0% vs -10.5% ± 4.0%; p = 0.006). In patients with coronary artery disease, longitudinal strain improved in the nonischemic myocardial segments in xenon patients. There were no changes in diastolic function between the groups.

CONCLUSIONS: Among comatose survivors of a cardiac cause out-of-hospital cardiac arrest, inhaled xenon combined with hypothermia was associated with greater recovery of left ventricular systolic function in comparison with hypothermia alone.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Saraste A, Ballo H, Arola O, et al. Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest-A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial. Crit Care Explor. 2021. PMID: 34345828. doi:10.1097/CCE.0000000000000502

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。